Filana Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Filana Therapeutics Inc. (formerly Cassava Sciences, Inc.) is a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders. The company's lead therapeutic candidate is simufilam, a proprietary oral small molecule designed to modulate the activity of the filamin A (FLNA) protein, which plays a critical role in regulating neuronal development. Following the discontinuation of its Phase 3 Alzheimer's disease program in late 2024 due to a lack of clinical efficacy, the company rebranded as Filana Therapeutics in March 2026 to align its corporate identity with its strategic pivot toward treating Tuberous Sclerosis Complex (TSC)-related epilepsy and other mTOR pathway disorders.
Research as of 24 Jul 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Following the failure of simufilam in Phase 3 Alzheimer's trials, the company pivoted its strategic focus to developing simufilam for Tuberous Sclerosis Complex (TSC)-related epilepsy, an orphan disease.
Expected impact: Establishes a new clinical development path for simufilam in an orphan disease indication with high unmet medical need, targeting a U.S. patient population of approximately 45,000 people.
Rebranded from Cassava Sciences, Inc. to Filana Therapeutics, Inc. (trading under ticker FLNA) to distance the company from past controversies, scientific misconduct allegations, and litigation associated with its former name.
Expected impact: Aims to restore stakeholder confidence, rebuild corporate reputation, and align the company's public identity directly with its scientific focus on the filamin A protein.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
In February 2025, the company entered into an exclusive worldwide license agreement with Yale University for intellectual property related to the treatment of epilepsy using simufilam. This forms the foundational IP for the company's TSC-related epilepsy program.
Terms: Filana agreed to pay Yale up to $4.5 million in milestone payments, plus low- to mid-single digit royalties on future commercial sales and minimum annual payments.
Collaborative preclinical research conducted with the TSC Alliance's Preclinical Consortium and PsychoGenics, Inc. to evaluate simufilam's efficacy in mouse models of severe TSC-related epilepsy.
Terms: Specific financial terms were not publicly disclosed.